USPTO serial 79286383
Serial No. 79286383
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 27, 2021
- Examiner
- LAVACHE, LINDA M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with Serial No. 79286383?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,046*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh Ann Lindquist
Leigh Ann Lindquist SUGHRUE MION, PLLC2000 PENNSYLVANIA AVENUE NW, SUITE 900Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biological, biochemical and biotechnological products and preparations for industrial and scientific purposes, namely, small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms as well as fragments, fractions, derivatives, components and lysates thereof; chemical, biological, biochemical and biotechnological chemical products and preparations for laboratory or research use and manufacturing use, namely, small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms as well as fragments, fractions, derivatives, components and lysates thereof | ACTIVE | — |
| 005 | Chemical, biological, biochemical and biotechnological products and preparations for medical, veterinary and pharmaceutical purposes for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation, namely, small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms as well as fragments, fractions and derivatives thereof; diagnostic preparations for medical and veterinary use; vaccines; healthcare preparations, medicines, medicinal preparations, pharmaceutical preparations and pharmaceutical substances for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation; pharmaceutical preparations and substances, namely, adjuvants, carriers for active ingredients and drug delivery systems comprising protein based capsids or particles for the release of therapeutic or diagnostic agents for medical use in humans or animals; biological implants comprising active ingredients | ACTIVE | — |
| 040 | Manufacture of pharmaceutical products, medicinal products, and medicaments from pharmaceutical compositions for others | ACTIVE | — |
| 042 | Scientific research and development for others, in particular in the fields of medicine, pharmacy, diagnostics, chemistry, biology, biochemistry and biotechnology; scientific research and development as well as biotechnological research and development services for others with regard to manufacturing pharmaceutical preparations, implants comprising active ingredients, carriers for active ingredients and drug delivery systems for medical use in humans or animals; development of pharmaceutical preparations, namely, medical products for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation, for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 27, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 23, 2022 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 29, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 5, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 5, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 27, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 27, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 9, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 9, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 6, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 20, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 20, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 20, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 4, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 4, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 4, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 4, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 4, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 16, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 16, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 16, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 16, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 16, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 16, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 5, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 16, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 15, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 11, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 10, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 6, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 12, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 8, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 5, 2020 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| May 28, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |